Daily Stock Pick â€” February 14, 2026

BIAF â€“ bioAffinity Technologies, Inc.

News: Record 2024 revenue and Medicare reimbursement support CyPath Lung ramp; raised capital in 2025 to extend runway.

Score (0â€“1000): 640

ADVICE: Buy

Certainty: 58%

Forecast image URL: https://stockscan.io/stocks/BIAF/forecast

Verifier note: Choosing BIAF as least-risk among microcaps: real 2024 revenue growth with Medicare reimbursement tailwind, albeit with dilution/low-cash risks; preferable to ACXP (going-concern/dilution) and DSY (Nasdaq deficiency). Sources: bioaffinitytech.com (2024 results, reimbursement), ir.bioaffinitytech.com (Q2â€™25 cash and Mayâ€™25 raise), acurxpharma.com (financing/Phase 3 planning), ir.bigtreeclouds.com & stocktitan.net (Nasdaq deficiency). ([bioaffinitytech.com](https://bioaffinitytech.com/bioaffinity-technologies-reports-record-9-4-million-revenue-for-2024/?utm_source=openai))

---
**Legend**
ğŸŸ¢ğŸŸ¢ğŸŸ¢ **Ultra Strong Buy** â€” Score > 800 â†’ â€œGuaranteed high returnâ€
ğŸŸ¢ **Strong Buy** â€” Score > 700 â†’ â€œAmazing Chancesâ€
ğŸŸ¡ **Buy** â€” Score â‰ˆ 600 â†’ â€œGreat Chancesâ€
ğŸ”´ **Ignore** â€” Score < 599 â†’ â€œIgnoreâ€

